This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

MiMedx Signs Agreement With Systagenix For Global Distribution Of EpiFix®

KENNESAW, Ga., March 19, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today the signing of a global distribution agreement with Systagenix, whereby Systagenix will co-market EpiFix®. The MiMedx branded and proprietary biologic implant specifically processed from amniotic tissue, EpiFix® offers a wide variety of wound healing and wound care options.

Based in Gatwick, United Kingdom, Systagenix will commence its launch of EpiFix® during March 2012. As part of its global distribution agreement with MiMedx, Systagenix will initially conduct the first phase of its global launch of EpiFix® throughout the United States, with launches in other countries to follow pending appropriate regulatory approvals. MiMedx will also continue to sell EpiFix® through its existing distributor channels.

EpiFix® is another of the MiMedx tissue offerings uniquely processed through the Company's proprietary Purion(SM) Process to optimize wound care and ease of use. EpiFix® is an allograft from amniotic tissue which has been shown to promote the healing of soft tissues. The Purion(SM) Process retains the amniotic growth factors inherent in and unique to placental tissue which promotes cellular ingrowth and enhanced healing.

EpiFix® has unique and differentiating characteristics such as its 5-year shelf life and stability at room temperature, its ease of handling and manipulation by physicians, its disinfection process that protects any compromise of the amniotic membrane delicate structure and its clinical history and testing results confirming that EpiFix® retains several growth factors associated with promoting cell proliferation.

Parker H. "Pete" Petit, Chairman and CEO, said, "We are very pleased with this opportunity to partner with Systagenix. The combined efforts of the Systagenix sales and marketing team with our existing sales, marketing and distribution channels will allow us to more effectively reach the advanced wound care therapies segment of the market."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,097.44 -105.93 -0.58%
S&P 500 2,098.48 -9.30 -0.44%
NASDAQ 4,967.7530 -12.1480 -0.24%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs